

**GRIFFITH UNIVERSITY, Institute for Glycomics - close the gaps in sarcoma diagnoses and treatment to deliver novel diagnostic technologies and precision treatment options to improve patient outcomes.**

We are delighted to announce a major new partnership with Griffith University's Institute for Glycomics, a translational biomedical research Institute based on the Gold Coast with a focus on developing vaccines, diagnostics and personalised treatments for a wide range of cancers, infectious diseases and neurological disorders. The Institute for Glycomics is a flagship biomedical research institute in Australia and has a strong track record of inventing new medicines for diseases that don't currently have solutions - from discovery to human clinical testing.

Our partnership with the Institute is focused on a vital sarcoma research project titled: Developing a novel diagnostic and treatment options for Sarcoma. Their aim is to close current gaps in accurate Sarcoma diagnosis and precision treatment to deliver novel diagnostics and treatment opportunities that improve patient outcomes and survival. The term sarcoma summarises a large number of different cancers that arise in the bones and connective tissues such as fat and muscle. While it is considered a rare cancer in adults, **sarcoma is a prevalent cancer in children representing about 20% of all childhood cancer diagnoses.**

The sarcoma project is a three-year research program led by Institute for Glycomics Director Professor Mark von Itzstein AO, in collaboration with clinicians at the Perez Scremini Children's Hospital in Uruguay, where sarcoma is prevalent in children, with advice and importantly providing the research project with valuable clinical specimens not available in the quantity in Australia.

We, along with a global philanthropic foundation have linked arms on this important research program and wholeheartedly believe this partnership will propel progress in sarcoma research to deliver solutions to the disease. The Institute's world-leading expertise and technologies have been recently acknowledged through the awarding of an Australian Cancer Research Foundation (ACRF) grant and an Australian Lions Childhood Cancer Research Foundation (ALCCRF) grant.

The ALCCRF grant of \$800,000 supports this \$2.2 million project.